by Alison Schuldt | Nov 15, 2019 | News
We are excited to be celebrating the launch of the AstraZeneca-Cancer Research UK Functional Genomics Centre today. Based in the Milner Therapeutics Institute, this collaborative team will be utilising CRISPR technologies to better understand cancer biology, creating... 
by Alison Schuldt | Oct 2, 2019 | News
A warm welcome to the team of Kathryn Lilley at the Cambridge Centre for Proteomics (CCP), who are moving into the Milner Therapeutics Institute this week! The group have just returned from the Human Proteome Organisation (HUPO) meeting in Australia, where Kathryn... 
by Alison Schuldt | Sep 26, 2019 | News
A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic... 
by Alison Schuldt | Sep 20, 2019 | News
The Milner Therapeutics Institute will form part of a University Enterprise Zone, created through a new government initiative announced today by Universities Minister Chris Skidmore. Research England, part of UK Research and Innovation, today announced 20 new... 
by Alison Schuldt | Sep 13, 2019 | News
We are delighted to welcome the group of Manav Pathania (Dept Oncology), who moved into the Milner Institute this month. The Pathania group have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis... 
by Alison Schuldt | Aug 2, 2019 | News
We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and...
